587-11-1

Basic information

• Product Name: fluorofibric acid
• Synonyms: fluorofibric acid;2-(4-fluorophenoxy)-2-methylpropanoic acid(SALTDATA: FREE);Propanoic acid, 2-(4-fluorophenoxy)-2-Methyl-;4-Fluorophenoxy-2-methylpropanoic acid
• CAS NO: 587-11-1
• Molecular Formula: C₁₀H₁₁FO₃
• Molecular Weight: 198.192
• Mol File: 587-11-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 83 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 304.1°Cat760mmHg
• Flash Point: 137.7°C
• Appearance: /
• Density: 1.224g/cm³
• Vapor Pressure: 0.000392mmHg at 25°C
• Refractive Index: 1.509
• PKA: 3.23±0.10(Predicted)
• CAS DataBase Reference: fluorofibric acid(CAS DataBase Reference)
• NIST Chemistry Reference: fluorofibric acid(587-11-1)
• EPA Substance Registry System: fluorofibric acid(587-11-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 587-11-1(Hazardous Substances Data)

Usage

General Description

Fluorofibric acid, also known as perfluorobutyric acid, is a perfluorinated carboxylic acid with the chemical formula C3F7COOH. It is a highly corrosive and toxic chemical that is a strong organic acid. Fluorofibric acid is commonly used in industrial applications, such as in the production of fluoropolymers and as a catalyst in organic synthesis. It is also used as a surfactant and in the manufacturing of pharmaceuticals and agricultural chemicals. However, due to its extremely corrosive and toxic nature, fluorofibric acid is regulated under various environmental and safety regulations to ensure safe handling and disposal. It is important to handle fluorofibric acid with caution and follow proper safety protocols when working with this chemical.

InChI:InChI=1/C10H11FO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)

Upstream product

• 587-12-2 ethyl 2-(4-fluorophenoxy)-2-methylpropanoate 
• 371-41-5 4-Fluorophenol 
• 2052-01-9 2-bromo-2-methylpropionic acid 
• 67-66-3 chloroform 
• 67-64-1 acetone 
• 57-15-8 1,1,1-trichloro-2-methyl-2-propanol 

Downstream Products

• 124206-53-7 2-(4-fluoro-2-nitrophenoxy)-2-methylpropanoic acid 
• 124188-14-3 3,3-dimethyl-8-fluoro-10-nitro-1,4-dioxaspiro<4.5>deca-6,8-dien-2-one 
• 124188-13-2 3,3-dimethyl-8-fluoro-8-nitro-1,4-dioxaspiro<4.5>deca-6,9-dien-2-one 
• 124188-16-5 2-(4-fluoro-2-nitrophenoxy)-2-methylpropanamide 
• 403-59-8 α-(4-fluoro-phenoxy)-isobutyric acid amide 
• 587-12-2 ethyl 2-(4-fluorophenoxy)-2-methylpropanoate 

Relevant articles and documents

Aryloxycyclohexyl amide AMPK agonist as well as preparation method and medical application thereof

The invention discloses an aryloxy cyclohexyl amide AMPK agonist as well as a preparation method and medical application thereof. The AMPK agonist is specifically an aryloxy cyclohexyl amide compound as shown in a formula (I) or pharmaceutically acceptable salt or ester or solvate of the aryloxy cyclohexyl amide compound. The aryloxy cyclohexyl amide compound with the AMPK agonistic activity has remarkable agonistic activity on AMPK at the cellular level, and can effectively activate an AMPK signal channel in vivo, so that the aryloxy cyclohexyl amide compound can be used for preparing medicines for preventing or treating various AMPK-mediated diseases.

Design, synthesis of novel, potent, selective, orally bioavailable adenosine A2A receptor antagonists and their biological evaluation

Our initial structure-activity relationship studies on 7-methoxy-4-morpholino-benzothiazole derivatives featured by aryloxy-2-methylpropanamide moieties at the 2-position led to identification of compound 25 as a potent and selective A2A adenosine receptor (A2AAdoR) antagonist with reasonable ADME and pharmacokinetic properties. However, poor intrinsic solubility and low to moderate oral bioavailability made this series unsuitable for further development. Further optimization using structure-based drug design approach resulted in discovery of potent and selective adenosine A2A receptor antagonists bearing substituted 1-methylcyclohexyl-carboxamide groups at position 2 of the benzothiazole scaffold and endowed with better solubility and oral bioavailability. Compounds 41 and 49 demonstrated a number of positive attributes with respect to in vitro ADME properties. Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat. Further, compound 49 displayed oral efficacy in 6-OHDA lesioned rat model of Parkinson diseases.

Synthesis and preliminary antihyperlipidaemic activities evaluation of andrographolide derivatives

Recent studies indicated that andrographolide was a potential antihyperlipidaemic therapeutic agent. In the paper, the synthesis of a series of andrographolide derivatives was described and their antihyperlipidaemic activities were evaluated in vivo. As compared with TG, TC, HDL-C and LDL-C concentrations, some of the derivatives exhibited better antihyperlipidaemic effects than positive control atromide. Therein, compound 6i, which was the most potent compound, could serve as a new lead for further development of antihyperlipidaemic agents.